Jul 2026 (Q1 FY27) — Sep 14, 2026
Kestra Medical Technologies Q1 FY27 — Strong Revenue Growth and Gross Margin Expansion
Read the full callKestra Medical Technologies (KMTS) earnings
- Jul 2026
- Jul 2026 (Q1 FY27)
- Apr 2026
Kestra Medical Technologies earnings: last reported Mon, 14 Sep 2026, for the quarter ended Jul 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 31.0 | +59.9% YoY | Quarterly, as filed | Quarter to Jul 2026 | Revenue from operations as filed. |
| Operating margin | -121.6 | +27.5 pts YoY | Operating profit / revenue | Quarter to Jul 2026 | For the quarter; a change is in percentage points. |
| Net profit | -44.1 | Quarterly, as filed | Quarter to Jul 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$29.37 +7.82% · +$2.13
Performance +19.3% 1Y
1Y: $24.61 on 17 Oct 2025 → $29.37. High $29.37 (19 Oct 2026), low $17.87 (10 Apr 2026).
- Previous close
- $27.24
- 52-week range
- $17.87 – $29.37
- One year
- +9.39%
Overview
- Symbol
- KMTS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Apr 2026 (Q4 FY26) — Jul 14, 2026
Kestra Medical Technologies Q4 FY26 — Strong Revenue Growth and Gross Margin Expansion
Read the full callEvery analysed call
Kestra Medical Technologies earnings calls (KMTS)
Financials
What the filings say
Net profit, year on year: −71% (quarter to jul 2026 against jul 2025).
| Line item | Oct 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 15 | 15 | 17 | 19 | 23 | 25 | 29 | 31 |
| Operating profit | -19 | -21 | -48 | -29 | -32 | -35 | -39 | -38 |
| Operating margin | −130.1% | −136.5% | −279.8% | −149.1% | −140.7% | −141.6% | −137.4% | −121.6% |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | -21 | -22 | -51 | -26 | -33 | -34 | -39 | -44 |
| Tax rate | −0.0% | −0.1% | −0.2% | −0.1% | −0.1% | −0.1% | −0.5% | −0.1% |
| Net profit | -20 | -22 | -52 | -26 | -33 | -34 | -39 | -44 |
| EPS ($ per share) | -1.19 | -1.25 | — | -0.50 | -0.64 | -0.61 | — | -0.75 |
| Line item | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|
| Equity capital | 20 | 51 | 58 |
| Reserves | -406 | -520 | -652 |
| Total liabilities | 78 | 90 | 99 |
| Fixed assets | 26 | 35 | 59 |
| Investments | — | — | 97 |
| Total assets | 46 | 296 | 358 |
| Line item | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|
| Cash from operations | -72 | -78 | -82 |
| Cash from investing | -12 | -23 | -203 |
| Cash from financing | 78 | 330 | 147 |
| Net cash flow | -7 | 229 | -138 |
| Capital expenditure | -12 | -23 | -35 |
| Free cash flow | -84 | -101 | -117 |
Insider filings
66 filings between Dec 3, 2025 and Sep 30, 2026.
Open market
decisions to buy or sellPurchases
$199.8K
1 purchase by 1 insider
Sales
$8.97M
45 sales by 11 insiders
42% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 20
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Webster Brian Daniel | — | $5.07M | Aug 17, 2026 |
| Mahboob Vaseem | — | $1.27M | Aug 7, 2026 |
| Umberger Traci S | — | $879.1K | Aug 4, 2026 |
| Ford Alfred J Jr | — | $793.7K | Aug 4, 2026 |
| Moran Timothy P. | — | $348.3K | Aug 3, 2026 |
| COHEN RAYMOND W | $199.8K | $97.5K | Sep 30, 2026 |
| Hanley Conor | — | $143.8K | Sep 8, 2026 |
| Ladone Mary Kay | — | $98.5K | Sep 8, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | COHEN RAYMOND W Director | Sale | 3,330 | $97.5K |
| Sep 21, 2026 | Kwo Elizabeth Director | Sale | 4,010 | $97.3K |
| Sep 9, 2026 | Reilly Kevin C Director | Award | 7,217 | — |
| Sep 9, 2026 | Schwartz Jeffrey Lawrence Director | Award | 7,217 | — |
| Sep 9, 2026 | Ladone Mary Kay Director | Award | 7,217 | — |
| Sep 9, 2026 | COHEN RAYMOND W Director | Award | 7,217 | — |
| Sep 9, 2026 | Hanley Conor Director | Award | 7,217 | — |
| Sep 9, 2026 | Kwo Elizabeth Director | Award | 7,217 | — |
| Sep 8, 2026 | Hanley Conor Director | Sale | 5,694 | $143.8K |
| Sep 8, 2026 | Reilly Kevin C Director | Sale | 2,932 | $73.7K |
| Sep 8, 2026 | Ladone Mary Kay Director | Sale | 3,908 | $98.5K |
| Sep 8, 2026 | Schwartz Jeffrey Lawrence Director | Sale | 3,890 | $97.9K |
| Aug 17, 2026 | Webster Brian Daniel See Remarks | Sale 10b5-1 plan | 15,000 | $412.2K |
| Aug 7, 2026 | Mahboob Vaseem Chief Financial Officer | Sale 10b5-1 plan | 500 | $13.2K |
| Aug 7, 2026 | Mahboob Vaseem Chief Financial Officer | Sale 10b5-1 plan | 25,787 | $667.2K |
| Aug 4, 2026 | Ford Alfred J Jr Chief Commercial Officer | Sale | 6,275 | $151.1K |
| Aug 4, 2026 | Webster Brian Daniel See Remarks | Sale | 48,625 | $1.19M |
| Aug 4, 2026 | Webster Brian Daniel See Remarks | Sale | 2,833 | $71.3K |
| Aug 4, 2026 | Webster Brian Daniel See Remarks | Sale | 442 | $11.5K |
| Aug 4, 2026 | Umberger Traci S See Remarks | Sale | 3,580 | $86.1K |
| Aug 4, 2026 | Mahboob Vaseem Chief Financial Officer | Sale 10b5-1 plan | 3,080 | $74.1K |
| Aug 4, 2026 | Mahboob Vaseem Chief Financial Officer | Sale 10b5-1 plan | 3,915 | $98.5K |
| Aug 3, 2026 | Umberger Traci S See Remarks | Sale | 7,590 | $181.1K |
| Aug 3, 2026 | Ford Alfred J Jr Chief Commercial Officer | Sale | 13,015 | $311.1K |
| Aug 3, 2026 | Moran Timothy P. Chief Business Officer | Sale | 2,380 | $56.6K |
| Aug 3, 2026 | Mahboob Vaseem Chief Financial Officer | Sale | 5,391 | $128.3K |
| Aug 3, 2026 | Webster Brian Daniel See Remarks | Sale | 13,017 | $311.4K |
| Jul 31, 2026 | Umberger Traci S See Remarks | Sale | 8,752 | $197.8K |
| Jul 31, 2026 | Mahboob Vaseem Chief Financial Officer | Sale | 8,817 | $199.3K |
| Jul 31, 2026 | Ford Alfred J Jr Chief Commercial Officer | Sale | 8,681 | $196.3K |
| Jul 31, 2026 | Moran Timothy P. Chief Business Officer | Sale | 8,759 | $198.0K |
| Jul 31, 2026 | Webster Brian Daniel See Remarks | Sale | 8,948 | $202.3K |
| Jul 30, 2026 | Webster Brian Daniel See Remarks | Sale | 7,857 | $178.5K |
| Jul 30, 2026 | Mahboob Vaseem Chief Financial Officer | Sale | 3,980 | $90.6K |
| Jul 30, 2026 | Ford Alfred J Jr Chief Commercial Officer | Sale | 5,936 | $135.1K |
| Jul 30, 2026 | Umberger Traci S See Remarks | Sale | 5,887 | $133.9K |
| Jul 30, 2026 | Moran Timothy P. Chief Business Officer | Sale | 4,117 | $93.8K |
| Jul 16, 2026 | Moran Timothy P. Chief Business Officer | Award | 39,113 | $0 |
| Jul 15, 2026 | Umberger Traci S See Remarks | Award | 58,832 | $0 |
| Jul 15, 2026 | Webster Brian Daniel See Remarks | Award 10b5-1 plan | 176,470 | $0 |
| Jul 15, 2026 | Webster Brian Daniel See Remarks | Sale 10b5-1 plan | 11,216 | $246.9K |
| Jul 15, 2026 | Webster Brian Daniel See Remarks | Sale 10b5-1 plan | 784 | $17.7K |
| Jul 15, 2026 | Webster Brian Daniel See Remarks | Sale 10b5-1 plan | 3,000 | $72.0K |
| Jul 15, 2026 | Mahboob Vaseem Chief Financial Officer | Award | 44,118 | $0 |
| Jul 15, 2026 | Ford Alfred J Jr Chief Commercial Officer | Award | 58,832 | $0 |
| Jun 30, 2026 | Moran Timothy P. Chief Business Officer | Award | 227 | $4.9K |
| Jun 30, 2026 | Umberger Traci S See Remarks | Award | 942 | $20.3K |
| Jun 15, 2026 | Webster Brian Daniel See Remarks | Sale 10b5-1 plan | 15,000 | $312.1K |
| Jun 3, 2026 | Mahboob Vaseem Chief Financial Officer | Award | 25,227 | $0 |
| Jun 3, 2026 | Moran Timothy P. Chief Business Officer | Award | 22,704 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for KESTRA MEDICAL TECHNOLOGIES, LTD.
Free account. Everything above stays public.
Write why you follow KESTRA MEDICAL TECHNOLOGIES, LTD. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading